FDA Approves Auvelity for Agitation in Alzheimer’s Disease - Summary - MDSpire

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.

  • By

  • Kathryn Wighton

  • April 30, 2026

  • 3 min

Share

Objective:

To report the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease.

Approach:
    Key Findings:
    • Agitation affects up to 76% of Alzheimer's patients.
    • Dextromethorphan-bupropion significantly improved agitation symptoms in clinical trials.
    • The treatment has a specific dosing regimen for agitation in Alzheimer's, differing from major depressive disorder.
    Interpretation:

    The approval of Auvelity provides a new treatment option for managing agitation in Alzheimer's patients, addressing a significant symptom that affects quality of life.

    Limitations:
    • The mechanism of action for agitation treatment remains unclear.
    • The relapse findings in ACCORD-2 should be interpreted with caution due to prior responder enrollment.
    Conclusion:

    Auvelity's approval represents a significant advancement in the treatment of agitation in Alzheimer's disease, with specific dosing and safety considerations.

    Sources:

Original Source(s)

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

  • by Kathryn Wighton

  • April 30, 2026

Related Content

Suicidal ideation after stroke: why standardized screening is essential for community-based prediction models

Aid in Dying Nears One Third of US

New laws in New York and Illinois will soon make medical aid in dying available to nearly one-third of Americans.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.